Works in Cancer Chemotherapy & Pharmacology, 2010, Vol 65, Issue 2

Results: 30

Quantitative structure–property relationships of camptothecins in humans.

Published in:

2010

By:

Xu C;
Barchet TM;
Mager DE;
Xu, Chao;
Barchet, Thomas M;
Mager, Donald E

Publication type:

journal article

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call((R))) in patients with unresectable hepatocellular carcinoma.

Published in:

2010

By:

Yamashita Y;
Taketomi A;
Itoh S;
Harimoto N;
Morita K;
Fukuhara T;
Ueda S;
Sanefuji K;
Sugimachi K;
Tajima T;
Maehara Y

Publication type:

Journal Article

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1[alpha] in tumor and normal cells.

Published in:

2010

By:

Du G;
Lin H;
Wang M;
Zhang S;
Wu X;
Lu L;
Ji L;
Yu L

Publication type:

Journal Article

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

Published in:

2010

By:

Tsimberidou AM;
Rudek MA;
Hong D;
Ng CS;
Blair J;
Goldsweig H;
Kurzrock R

Publication type:

Journal Article

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.

Published in:

2010

By:

Robert F;
Harper K;
Ackerman J;
Gupta S

Publication type:

Journal Article

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-[alpha]5[beta]1 integrin monoclonal antibody (volociximab) in cancer patients.

Published in:

2010

By:

Ng CM;
Bai S;
Takimoto CH;
Tang MT;
Tolcher AW

Publication type:

Journal Article

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 399, doi. 10.1007/s00280-009-1118-2

By:

Leal, Ticiana;
Robins, H. Ian

Publication type:

Article

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 403, doi. 10.1007/s00280-009-1147-x

By:

Loganayagam, Aathavan;
Arenas-Hernandez, Monica;
Fairbanks, Lynette;
Ross, Paul;
Sanderson, Jeremy D.;
Marinaki, Anthony M.

Publication type:

Article

Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 219, doi. 10.1007/s00280-009-1024-7

By:

Kurebayashi, Junichi;
Nukatsuka, Mamoru;
Sonoo, Hiroshi;
Uchida, Junji;
Kiniwa, Mamoru

Publication type:

Article

Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 319, doi. 10.1007/s00280-009-1036-3

By:

Ntukidem, Nse;
Arce-Lara, Carlos;
Otterson, Gregory A.;
Kraut, Eric;
Cataland, Spero;
Bekaii-Saab, Tanios

Publication type:

Article

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 277, doi. 10.1007/s00280-009-1032-7

By:

Gangjun Du;
Haihong Lin;
Mei Wang;
Shuo Zhang;
Xianchuang Wu;
Linlin Lu;
Liyan Ji;
Lijuan Yu

Publication type:

Article

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.

Published in:

2010

By:

Hyun Young Woo;
Si Hyun Bae;
Jun Young Park;
Kwang Hyub Han;
Ho Jong Chun;
Byung Gil Choi;
Im, Hyeon U.;
Jong Young Choi;
Seung Kew Yoon;
Jae Youn Cheong;
Sung Won Cho;
Byoung Kuk Jang;
Jae Seok Hwang;
Sang Gyune Kim;
Young Seok Kim;
Yeon Seok Seo;
Hyung Joon Yim;
Soon Ho Um

Publication type:

Report

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 243, doi. 10.1007/s00280-009-1028-3

By:

Shimizu, Toshio;
Okamoto, Isamu;
Tamura, Kenji;
Satoh, Taroh;
Miyazaki, Masaki;
Akashi, Yusaku;
Ozaki, Tomohiro;
Fukuoka, Masahiro;
Nakagawa, Kazuhiko

Publication type:

Article

Quantitative structure–property relationships of camptothecins in humans.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 325, doi. 10.1007/s00280-009-1037-2

By:

Chao Xu;
Barchet, Thomas M.;
Mager, Donald E.

Publication type:

Article

Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 259, doi. 10.1007/s00280-009-1030-9

By:

Muh-Hwa Yang;
Peter Mu-Hsin Chang;
Cheng-Hwai Tzeng;
Shyue-Yih Chang;
Pen-Yuan Chu;
Shyh-Kuan Tai;
Tung-Lung Tsai;
Yi-Feng Wang;
Jui-Lin Huang;
Hung-Ming Wang;
Po-Min Chen

Publication type:

Article

Phase 1 first-in-human clinical study of S- trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 235, doi. 10.1007/s00280-009-1027-4

By:

Tsimberidou, Apostolia Maria;
Rudek, Michelle A.;
Hong, David;
Ng, Chaan S.;
Blair, Jessica;
Goldsweig, Howard;
Kurzrock, Razelle

Publication type:

Article

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 227, doi. 10.1007/s00280-009-1026-5

By:

Robert, Francisco;
Harper, Karen;
Ackerman, Judie;
Gupta, Sunil

Publication type:

Article

Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 309, doi. 10.1007/s00280-009-1035-4

By:

Das, Tanushree;
Patra, Falguni;
Mukherjee, Biswajit

Publication type:

Article

Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 267, doi. 10.1007/s00280-009-1031-8

By:

Bastos-Pereira, Amanda Leite;
Lugarini, Daiana;
de Oliveira-Christoff, Adriana;
Ávila, Thiago Vinicius;
Teixeira, Simone;
do Rocio Andrade Pires, Amanda;
Muscará, Marcelo Nicolás;
Cadena, Sílvia Maria Suter Correia;
Donatti, Lucélia;
da Silva de Assis, HelenaCristina;
Acco, Alexandra

Publication type:

Article

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 207, doi. 10.1007/s00280-009-1023-8

By:

Ng, Chee C.;
Bai, S.;
Takimoto, C. H.;
Tang, M. T.;
Tolcher, A. W.

Publication type:

Article

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Published in:

2010

By:

Kummar, Shivaani;
Gutierrez, Martin E.;
Gardner, Erin R.;
Figg, William D.;
Melillo, Giovanni;
Dancey, Janet;
Sausville, Edward A.;
Conley, Barbara A.;
Murgo, Anthony J.;
Doroshow, James H.

Publication type:

Report

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 353, doi. 10.1007/s00280-009-1041-6

By:

Thiessen, Brian;
Stewart, Clinton;
Ming Tsao;
Kamel-Reid, Suzanne;
Schaiquevich, Paula;
Mason, Warren;
Easaw, Jacob;
Belanger, Karl;
Forsyth, Peter;
McIntosh, Lynn;
Eisenhauer, Elizabeth

Publication type:

Article

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 335, doi. 10.1007/s00280-009-1039-0

By:

Azzariti, Amalia;
Porcelli, Letizia;
Simone, Grazia M.;
Quatrale, Anna E.;
Colabufo, Nicola A.;
Berardi, Francesco;
Perrone, Roberto;
Zucchetti, Massimo;
D'Incalci, Maurizio;
Jian Ming Xu;
Paradiso, Angelo

Publication type:

Article

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 251, doi. 10.1007/s00280-009-1029-2

By:

Fujita, Ken-ichi;
Ando, Yuichi;
Yamamoto, Wataru;
Miya, Toshimichi;
Endo, Hisashi;
Sunakawa, Yu;
Araki, Kazuhiro;
Kodama, Keiji;
Nagashima, Fumio;
Ichikawa, Wataru;
Narabayashi, Masaru;
Akiyama, Yuko;
Kawara, Kaori;
Shiomi, Mari;
Ogata, Hiroyasu;
Iwasa, Hiroyasu;
Okazaki, Yasushi;
Hirose, Takashi;
Sasaki, Yasutsuna

Publication type:

Article

Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 289, doi. 10.1007/s00280-009-1033-6

By:

Nathwani, Seema-Maria;
Butler, Stephen;
Meegan, Mary J.;
Campiani, Giuseppe;
Lawler, Mark;
Williams, D. Clive;
Zisterer, Daniela M.

Publication type:

Article

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 363, doi. 10.1007/s00280-009-1042-5

By:

Endo, Mika;
Miwa, Masanori;
Ura, Masako;
Tanimura, Hiromi;
Taniguchi, Kenji;
Miyazaki, Yoko;
Ohwada, Jun;
Tsukazaki, Masao;
Niizuma, Satoshi;
Murata, Takeshi;
Ozawa, Sawako;
Suda, Hitomi;
Ogawa, Kotaro;
Nanba, Eitaro;
Nagao, Shunsuke;
Shimma, Nobuo;
Yamada-Okabe, Hisafumi

Publication type:

Article

Bexarotene: a promising anticancer agent.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 201, doi. 10.1007/s00280-009-1140-4

By:

Liyan Qu;
Xiuwen Tang

Publication type:

Article

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 301, doi. 10.1007/s00280-009-1034-5

By:

Yamashita, Yo-ichi;
Taketomi, Akinobu;
Itoh, Shinji;
Harimoto, Norifumi;
Morita, Kazutoyo;
Fukuhara, Takasuke;
Ueda, Shigeru;
Sanefuji, Kensaku;
Sugimachi, Keishi;
Tajima, Tsuyoshi;
Maehara, Yoshihiko

Publication type:

Article

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.

Published in:

2010

By:

Metro, Giulio;
Fabi, Alessandra;
Mirri, Maria A.;
Vidiri, Antonello;
Pace, Andrea;
Carosi, Mariantonia;
Russillo, Michelangelo;
Maschio, Marta;
Giannarelli, Diana;
Pellegrini, Domenica;
Pompili, Alfredo;
Cognetti, Francesco;
Carapella, Carmine M.

Publication type:

Report

The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 2, p. 347, doi. 10.1007/s00280-009-1040-7

By:

Yan Zhang;
Yanyan Jia;
Xinyou Liu;
Linna Liu;
Qingwei Wang;
Aidong Wen

Publication type:

Article

Works in Cancer Chemotherapy & Pharmacology, 2010, Vol 65, Issue 2

Quantitative structure–property relationships of camptothecins in humans.

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call((R))) in patients with unresectable hepatocellular carcinoma.

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1[alpha] in tumor and normal cells.

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-[alpha]5[beta]1 integrin monoclonal antibody (volociximab) in cancer patients.

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.

Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.

Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells.

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors.

Quantitative structure–property relationships of camptothecins in humans.

Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study.

Phase 1 first-in-human clinical study of S- trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.

Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat.

Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α<sub>5</sub>β<sub>1</sub> integrin monoclonal antibody (volociximab) in cancer patients.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.

Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

Bexarotene: a promising anticancer agent.

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call<sup>®</sup>) in patients with unresectable hepatocellular carcinoma.

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.

The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma.